Cart
sales@molnova.com
Lanperisone HCl
CAS No. 116287-13-9
Lanperisone HCl( —— )
Catalog No. M36367 CAS No. 116287-13-9
Lanperisone HCl (NK 433) is a novel orally available centrally acting muscle relaxant with anticancer activity and inhibits mono- and polysynaptic reflex potentials.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 683 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1371 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2475 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLanperisone HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionLanperisone HCl (NK 433) is a novel orally available centrally acting muscle relaxant with anticancer activity and inhibits mono- and polysynaptic reflex potentials.
-
DescriptionLanperisone HCl (NK 433) is a novel orally available centrally acting muscle relaxant with anticancer activity and inhibits mono- and polysynaptic reflex potentials.Lanperisone HCl acts by inducing non-apoptotic cell death in the cell cycle and translational independence.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number116287-13-9
-
Formula Weight321.77
-
Molecular FormulaC15H19ClF3NO
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC([C@@H](CN1CCCC1)C)(=O)C2=CC=C(C(F)(F)F)C=C2.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Gardenoside
Gardenoside can inhibit the secretion of gastric juice and reduce the role of pancreatic amylase.
-
BTT-3033
BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation.
-
Cl-amidine hydrochlo...
Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor (IC50: 5.9 μM for PAD4).
